Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
20.15B
Market cap20.15B
Price-Earnings ratio
15.80
Price-Earnings ratio15.80
Dividend yield
Dividend yield
Average volume
1.70M
Average volume1.70M
High today
$99.94
High today$99.94
Low today
$99.00
Low today$99.00
Open price
$99.04
Open price$99.04
Volume
1.38K
Volume1.38K
52 Week high
$112.29
52 Week high$112.29
52 Week low
$53.56
52 Week low$53.56

Stock Snapshot

Incyte(INCY) stock is priced at $99.00, giving the company a market capitalization of 20.15B. It carries a P/E multiple of 15.80.

As of 2026-03-02, Incyte(INCY) stock has fluctuated between $99.00 and $99.94. The current price stands at $99.00, placing the stock 0.0% above today's low and -0.9% off the high.

Incyte(INCY) shares are trading with a volume of 1.38K, against a daily average of 1.7M.

During the past year, Incyte(INCY) stock moved between $53.56 at its lowest and $112.29 at its peak.

During the past year, Incyte(INCY) stock moved between $53.56 at its lowest and $112.29 at its peak.

INCY News

Simply Wall St 2d
Incyte Valuation Check After EMA Boost For Olumiant Alopecia Approval Potential

Incyte (INCY) is back in focus after Eli Lilly and Incyte received a positive opinion from the European Medicines Agency for extending Olumiant to adolescents w...

Incyte Valuation Check After EMA Boost For Olumiant Alopecia Approval Potential
TipRanks 6d
Top Incyte Executive Makes a Major Move With His Company Shares

New insider activity at Incyte ( (INCY) ) has taken place on February 23, 2026. In a notable insider move at Incyte, President of R&D Pablo Cagnoni has sold 18...

Analyst ratings

46%

of 28 ratings
Buy
42.9%
Hold
46.4%
Sell
10.7%

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.